Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00242775 | Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg | PHASE3 | COMPLETED | 2,100 | — | — | May 1, 2005 | May 1, 2006 | Jan 24, 2011 | 143 | Argentina, Australia +15 |
| Name | Type | Description |
|---|---|---|
| Budesonide/formoterol Turbuhaler | DRUG | - |
| Salmeterol/fluticasone Diskus | DRUG | - |
Inclusion Criteria: * Diagnosed with asthma since at least 6 months prior to first visit * Prescribed daily use of glucocorticosteroids for at least 3 months prior to first visit * At least one asthma exacerbation more than one but less than twelve months prior to first visit Exclusion Criteria: ...